@brandon-beaber.bsky.social
📤 281
📥 19
📝 733
He Ignored Double Vision… The Damage Came Later. A story about delayed MS diagnosis by
@aaronbostermd.bsky.social
youtu.be/uvpN18SDYSw?...
loading . . .
He Ignored Double Vision… The Damage Came Later
YouTube video by Aaron Boster MD
https://youtu.be/uvpN18SDYSw?si=b3_zQjHJJ0bcg6YO
about 6 hours ago
0
0
0
NVG-291
youtube.com/shorts/g48eN...
loading . . .
NVG-291
YouTube video by Dr. Brandon Beaber
https://youtube.com/shorts/g48eN5vk7ds?si=6jMitZzDjbLbDcJI
3 days ago
0
1
0
Upcoming videos: 4/22/26: MS drug Classes 4/29/26: Dr. Boster is right about THIS 5/6/26: THIS gets misdiagnosed as MS 5/13/26: 9 Stupid things doctors believed about MS. Let me know if you have other video ideas
www.youtube.com/@DrBrandonBe...
loading . . .
Dr. Brandon Beaber
I am a board-certified neurologist with subspecialty training in multiple sclerosis and other immunological diseases of the nervous system, and I post new videos about MS every Wednesday Check out my...
https://www.youtube.com/@DrBrandonBeaber
4 days ago
0
3
0
Low vitamin D in multiple sclerosis is linked to higher rates of relapses, but these is no clear association with disability (as measured by EDSS) according to this meta-analysis
pubmed.ncbi.nlm.nih.gov/41983136/
4 days ago
0
1
0
Multiple Sclerosis, the Gut, and Entyvio. A Fascinating Study.
youtu.be/XwGr6wn8u30?...
loading . . .
Multiple Sclerosis, the Gut, and Entyvio. A Fascinating Study.
YouTube video by Dr. Brandon Beaber
https://youtu.be/XwGr6wn8u30?si=kwb7ANZ_rdoN7r3e
5 days ago
0
0
0
Multiple sclerosis disease duration vs. level of disability. There is a correlation but perhaps not as strong as you might expect. From North American Research Committee on Multiple Sclerosis (NARCOMS)
www.neurology.org/doi/10.1212/...
6 days ago
0
3
1
As a reminder, the benefits of IV steroids over oral steroids are largely psychological. Concentrations in the blood of IV methylprednisolone (solumedrol) and oral prednisone are similar by 4 hours.
pubmed.ncbi.nlm.nih.gov/15452302/
7 days ago
1
1
0
The medical mystery of "wearing off effect" between doses of tysabri/tyruko (feeling worse MS symptoms between doses). Reported symptoms do not significantly correlate with receptor saturation.
pubmed.ncbi.nlm.nih.gov/41965149/
loading . . .
The wearing-off effect with natalizumab: Back to the drawing board - PubMed
The wearing-off effect with natalizumab: Back to the drawing board
https://pubmed.ncbi.nlm.nih.gov/41965149/
8 days ago
0
0
1
An explanation of Adult Onset Leukodystrophy which can mimic multiple sclerosis by Dr. Manzoor Ahmed l
youtu.be/DL5HnSL8cNw?...
loading . . .
Dr. Manzoor Ahmed l Adult Onset Leukodystrophy
YouTube video by MCO Healthcare Conferences
https://youtu.be/DL5HnSL8cNw?si=2DkjWlK-JNEVw7RM
9 days ago
0
0
0
44-year-old woman with vision loss/confusion. MRI brain shows enhancing periventricular lesions. Multiple Sclerosis? No! Diagnosis? Prepare to fail miserably
11 days ago
0
0
0
Microglial activation in the brain as measured by TSPO PET scan (left) may have a stronger correlation with disability in multiple sclerosis than T1 dark lesions ("black holes," right)
journals.lww.com/co-neurology...
12 days ago
0
1
2
Christina Applegate Autobiography "You with the Sad Eyes" Reviewed by Neurologist
youtu.be/iJd1CH9qmcc?...
loading . . .
Christina Applegate Autobiography "You with the Sad Eyes" Reviewed by Neurologist
YouTube video by Dr. Brandon Beaber
https://youtu.be/iJd1CH9qmcc?si=hcglog6fnaCwBuUj
12 days ago
0
1
0
The STRATA dataset. Those with multiple sclerosis originally randomized to tysabri had less disability than those randomized to placebo even many years later, suggesting early treatment does make a difference.
pmc.ncbi.nlm.nih.gov/articles/PMC...
13 days ago
0
2
1
How strong is the correlation between industry payments to doctors and prescribing brand name drugs over generics? This study found receiving > $1000 was linked to about a 4-fold increased use of copaxone over generic glatiramer
www.neurology.org/doi/10.1212/...
loading . . .
Industry Payments and Prescribing of Brand-Name Multiple Sclerosis Medications in Medicare | Neurology
ObjectivesIndustry payments to clinicians influence prescribing, limiting use of lower-cost generics, and leading to nonadherence. This study of prescribing for multiple sclerosis examined whether pay...
https://www.neurology.org/doi/10.1212/WNL.0000000000214834
14 days ago
0
0
0
A paramagnetic rim lesion in a juxtacortical lesion with a dark edge (upper left) in multiple sclerosis seen on 7T MRI.
academic.oup.com/braincomms/a...
17 days ago
0
2
1
Considerations for family planning with multiple sclerosis. Authors @drruthdobson @KerstinHellwig
pubmed.ncbi.nlm.nih.gov/41925496/
17 days ago
0
3
2
50 year old man with migraine w/aura with vision loss and thinning of the retinal nerve fiber layer on OCT. MRI showed this. Multiple sclerosis? No! He has a genetic leukodystrophy and has variants in the gene POLG (p.Thr251Ile and p.Pro587Leu).
pubmed.ncbi.nlm.nih.gov/41925503/
loading . . .
Adult-Onset Leukodystrophies Mimicking Multiple Sclerosis - PubMed
Although individually rare, adult-onset leukodystrophies represent a non-negligible diagnostic challenge to clinicians assessing patients for MS. Patients with adult-onset leukodystrophies often present with multifocal white matter involvement that may mimic MS lesions. Their variable clinical prese …
https://pubmed.ncbi.nlm.nih.gov/41925503/
17 days ago
0
1
0
Fasting Multiple Sclerosis Johns Hopkins Research
youtube.com/shorts/HAnOJ...
loading . . .
Fasting Multiple Sclerosis Johns Hopkins Research
YouTube video by Dr. Brandon Beaber
https://youtube.com/shorts/HAnOJgyPbKU?si=BFZR6siiSIHvAgkm
17 days ago
0
2
1
Different approaches to the treatment of multiple sclerosis with disease modifying therapy in graphical form.
pubmed.ncbi.nlm.nih.gov/41925508/
17 days ago
0
0
1
I'm Selling Out to Big Pharma
youtu.be/K0wqXgprAi4?...
loading . . .
I'm Selling Out to Big Pharma
YouTube video by Dr. Brandon Beaber
https://youtu.be/K0wqXgprAi4?si=gpA_pIdWjolU0tmb
19 days ago
0
1
1
This Canadian study suggests a possible link between processed food and pediatric multiple sclerosis. "Each additional 10% in ultra-processed food consumption was associated with a 35% higher odds" (adjusted odds ratio [aOR]=1.35, 95% CI 1.05, 1.73)
pubmed.ncbi.nlm.nih.gov/41916081/
20 days ago
0
1
1
Query for the neurologists. Healthy 37-year-old male. Incidental asymptomatic right middle cerebral artery stenosis noted on a Prenuvo scan. What is your recommendation?
20 days ago
0
0
0
A schematic on how nutrition could affect the pathogenesis of multiple sclerosis
pubmed.ncbi.nlm.nih.gov/41892626/
22 days ago
0
1
1
MRI brain findings in multiple sclerosis. T2 lesions (A), black holes (B), paramagnetic rim lesions (C), and the central vein sign (D)
pubmed.ncbi.nlm.nih.gov/41884359/
24 days ago
0
3
1
meta analysis of 17 studies on b-cell depleters (rituximab, briumvi, ocrevus) standard vs. extended interval dosing (taking it less often) have comparable results in terms of relapse rates and MRI activity, though no major difference in serious infections
pubmed.ncbi.nlm.nih.gov/41890616/
loading . . .
Safety and efficacy of extended versus standard interval dosing of anti-CD20 therapy in multiple sclerosis - A meta-analysis - PubMed
Data from observational studies suggests that EID of anti-CD20 therapy may have a comparable efficacy and safety profile compared to SID.
https://pubmed.ncbi.nlm.nih.gov/41890616/
24 days ago
0
3
1
Risk of "rebound" relapse after stopping zeposia for multiple sclerosis. It was 30.6% within two months for 1679 participants who did not start commercial zeposia at the end of the DAYBREAK single arm open label extension trial. Most relapses not severe.
pubmed.ncbi.nlm.nih.gov/41891136/
loading . . .
Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants - PubMed
Most participants did not relapse within 90 days following ozanimod discontinuation. Post-treatment relapse cases suggestive of a rebound effect were not observed.
https://pubmed.ncbi.nlm.nih.gov/41891136/
24 days ago
0
1
1
Dr. Shay Taylor-Allen matches in anesthesiology residency at Yale New Haven Hospital where she previously worked as a janitor!
youtu.be/7zxMBRj8-I8?...
loading . . .
FULL CIRCLE: Janitor returns to hospital as doctor
YouTube video by Fox News Clips
https://youtu.be/7zxMBRj8-I8?si=u7zztB3Mh8N2x5fl
24 days ago
0
1
0
Multiple Sclerosis with Alexia without Agraphia
youtube.com/shorts/jKjwh...
loading . . .
Multiple Sclerosis with Alexia without Agraphia
YouTube video by Dr. Brandon Beaber
https://youtube.com/shorts/jKjwhlWrSWU?si=j2W_cavxxz60Lgfz
24 days ago
0
1
1
Tysabri vs. Tyruko for MS. Even though a randomized trial suggests these two natalizumab formulations are equivalent and drug levels remain stable after switching, some people are dissatisfied with the results and report more side effects.
pubmed.ncbi.nlm.nih.gov/41861706/
30 days ago
0
1
1
Ketogenic Diet MS Research at University of Virginia
youtube.com/shorts/SNaKz...
loading . . .
Ketogenic Diet MS Research at University of Virginia
YouTube video by Dr. Brandon Beaber
https://youtube.com/shorts/SNaKzw4iSRI?si=HxzuFTPKS7AJbAJo
about 1 month ago
0
1
1
A woman was diagnosed with MS in 2019. A cerebrospinal fluid sample (obtained from spinal anaesthesia in a research study) 15 years prior showed antibodies against Epstein-Barr virus (EBV). A case report from Spain
pubmed.ncbi.nlm.nih.gov/41841779/
loading . . .
Intrathecal synthesis of Epstein-Barr virus antibodies 15 years before onset of multiple sclerosis - PubMed
A 48-year-old woman was diagnosed with multiple sclerosis (MS) in 2019. She participated with blood and cerebrospinal fluid samples as a spinal anaesthesia surgery patient for a case-control study on viruses and MS in 2003. The study had already demonstrated intrathecal antibody synthesis (ITS) to E …
https://pubmed.ncbi.nlm.nih.gov/41841779/
about 1 month ago
0
2
1
Potential treatments of Epstein-Barr virus (EBV) which could be used in multiple sclerosis: vaccines, antivirals, immunotherapy.
pubmed.ncbi.nlm.nih.gov/41846093/
about 1 month ago
0
2
1
Using rituximab for multiple sclerosis as infrequently as every 18-24 months in those who were previously stable is associated low disease activity (MRI disease activity and/or relapses in only 2.4%. From Southern California, USA
journals.sagepub.com/doi/10.1177/...
loading . . .
Sage Journals: Discover world-class research
Subscription and open access journals from Sage, the world's leading independent academic publisher.
https://journals.sagepub.com/doi/10.1177/13524585261430130
about 1 month ago
0
1
1
Innocare Pharma intends to begin research on an investigational multiple sclerosis drug ICP-538 which works by degrading VAV1 protein involved in the function of lymphocytes (b and t cells)
multiplesclerosisnewstoday.com/news-posts/2...
loading . . .
Trial of autoimmune disease treatment ICP-53 launches in China
A clinical trial in China testing ICP-538, a treatment candidate for MS and other autoimmune diseases, has dosed its first healthy volunteer.
https://multiplesclerosisnewstoday.com/news-posts/2026/03/18/trial-testing-autoimmune-disease-treatment-icp-538-ms-launches-china/
about 1 month ago
0
2
1
What actually happens to people with MS 6 years after starting mavenclad. 63.2% remain free of any new treatments (data from Germany) after the initial two annual courses, but other receive further mavenclad courses or a different drug.
link.springer.com/article/10.1...
about 1 month ago
0
2
1
Fenebrutinib Update. Clinical Trial Results, Liver Disease, and Death:
www.youtube.com/watch?v=xSFm...
loading . . .
Fenebrutinib Update. Clinical Trial Results, Liver Disease, and Death
YouTube video by Dr. Brandon Beaber
https://www.youtube.com/watch?v=xSFmZLdWd5U&lc=UgyTHLSfWgkUfKFvMup4AaABAg
about 1 month ago
0
2
1
Multiple sclerosis prevalence and race. Data from the All of Us Research Program.
pubmed.ncbi.nlm.nih.gov/41833242/
about 1 month ago
0
1
1
The prevalence of multiple sclerosis in Lithuania is about 1 in 800.
pmc.ncbi.nlm.nih.gov/articles/PMC...
loading . . .
The Lithuanian multiple sclerosis registry: current framework and quality challenges
This article presents the current structure, data collection methods, coverage, and limitations of the Lithuanian Multiple Sclerosis (MS) Registry. The Lithuanian MS Registry, established by the Lithuanian Neurologists' Association, began its ...
https://pmc.ncbi.nlm.nih.gov/articles/PMC12967925/
about 1 month ago
0
1
1
Multiple Sclerosis is still extremely rate in Korea with a prevalence of only 1 in 29,000
pubmed.ncbi.nlm.nih.gov/41818658/
about 1 month ago
0
2
0
Can hematopoietic stem cell transplant, perhaps the strongest disease modifying therapy in MS, reverse paramagnetic rim lesions on 7T MRI? According to this small case series (n = 7), no. None of the lesions resolved.
pubmed.ncbi.nlm.nih.gov/41821410/
about 1 month ago
0
0
0
The risk of shingles with different multiple sclerosis disease modifying therapies. The risk is highest with gilenya, Lemtrada, and Mavenclad. Ocrevus/Kesimpta surprisingly were not linked to increased risk.
pubmed.ncbi.nlm.nih.gov/41823332/
about 1 month ago
0
0
0
Invisible Symptoms in "Benign" Multiple Sclerosis
youtube.com/shorts/MTyBg...
loading . . .
Invisible Symptoms in "Benign" Multiple Sclerosis
YouTube video by Dr. Brandon Beaber
https://youtube.com/shorts/MTyBgyBR7DA?si=cpKnylMY7vlam3XW
about 1 month ago
0
1
0
Multiple Sclerosis & Kappa Free Light Chains Explained
youtu.be/6HN4HKfj5NE?...
loading . . .
Multiple Sclerosis & Kappa Free Light Chains
YouTube video by Dr. Brandon Beaber
https://youtu.be/6HN4HKfj5NE?si=MEyYDCrClrwTeFHL
about 1 month ago
0
3
1
My analysis of excess deaths with fenebrutinib in the FENhance 1/2 and FENtrepid trials suggests this would be extremely unlikely to occur by random chance. By X^2, p-value is 0.0016. By Fisher exact, p ~ 0.0019. But why?
about 1 month ago
0
1
1
Liver enzymes in the FENtrepid Trial (fenebrutinib vs. ocrevus in primary progressive MS). Much more liver enzyme elevation with fenebrutinib as expected, though all cases resolved after stopping the drug and none lead to permanent liver failure.
assets.roche.com/f/176343/x/4...
about 1 month ago
0
2
1
Deaths in the FENtrepid Trial (fenebrutinib vs. ocrevus in primary progressive MS). 7 deaths with fenebrutinib vs. only one with Ocrevus. Concerning, but there is no specific pattern.
assets.roche.com/f/176343/x/4...
about 1 month ago
0
1
1
reposted by
Prof G
about 1 month ago
It is a pity we didn't do it before the new McDonald diagnostic criteria were developed. The process is underpinned by Viquar Chamoun's work on neurosarcoidosis as part of his MD. Beyond the 2024 McDonald Criteria for Defining and Diagnosing Multiple Sclerosis
buff.ly/u6HBOkS
0
4
4
FENtrepid (Fenebrutinib vs. ocrevus in PPMS). compositive disability similar. nonsignificant trend favoring fenebrutinib. HR: 0.88 (95% CI 0.75–1.03) Data driven mostly by timed 25-foot-walk. 9-hole peg test favored fenebrutinib (26% less progression)
assets.roche.com/f/176343/x/4...
about 1 month ago
0
1
1
Dr. Amit Bar-Or summarizes the primary results from the Phase III FENtrepid study of fenebrutinib versus ocrevus in primary progressive MS
youtu.be/o3sxq3rnpsA?...
loading . . .
Primary results from the Phase III FENtrepid study of fenebrutinib versus ocrelizumab in PPMS
YouTube video by VJNeurology
https://youtu.be/o3sxq3rnpsA?si=PYhb1plAVJrzEmdP
about 1 month ago
0
3
1
serum neurofilament light chain (a marker of central nervous system injury in multiple sclerosis) does not correlate with "no evidence of disease activity" (NEDA-3) in people who are taking disease modifying therapy.
link.springer.com/article/10.1...
about 1 month ago
0
2
1
Load more
feeds!
log in